Early studies in mice demonstrated that tumor-specific cytotoxic T lymphocytes (CTLs) could control tumor growth and metastasis. The identification of T cell-recognizing tumor-associated antigens (TAAs) in human cancer, particularly in melanoma (i.e. MAGE, MART-1, gp100, tyrosinase, and TRP), 1, 2) facilitated the development of cancer immunotherapy based on TAA-vaccination with adjuvants to elicit tumor-specific CTLs.
Early studies in mice demonstrated that tumor-specific cytotoxic T lymphocytes (CTLs) could control tumor growth and metastasis. The identification of T cell-recognizing tumor-associated antigens (TAAs) in human cancer, particularly in melanoma (i.e. MAGE, MART-1, gp100, tyrosinase, and TRP), 1, 2) facilitated the development of cancer immunotherapy based on TAA-vaccination with adjuvants to elicit tumor-specific CTLs.
3) However, this immunological approach limits the application of this system only to certain cancer patients because TAAs are not yet identified for most of human cancers. Additionally, the expression levels of known TAAs that may be applicable for immunotherapy vary between tumor cells isolated from patients with cancer. 4) Therefore, it is very difficult to predict which TAA would generate an effective anti-tumor immune response that would make it appropriate for use as a vaccine component for a specific patient.
To overcome this limitation, several researchers have attempted to develop a vaccine strategy using tumor cell-lysate (TCL) as a possible source of TAA.
5) The use of TCL prepared from surgically removed tumors is a promising approach to induce a broader T cell-immune response not only to defined TAAs but also to unknown TAAs. In TCL-based cancer immunotherapy, the development of both an antigendelivery system and an adjuvant that can efficiently prime and propagate CTLs specific for TAAs included in the TCL is required for achieving sufficient therapeutic effect. CTLs are activated by antigen-presenting cells (APCs), including dendritic cells (DCs), through the major histocompatibility complex (MHC) class I-restricted antigen presentation pathway. Peptides presented on MHC class I molecules are derived in most situations exclusively from endogenous antigens synthesized by cells. Antigens in the extracellular fluids fail to gain access to the MHC class I-pathway in most cells, although class I-presentation of endocytosed antigens also occurs in APCs under certain circumstances. 6, 7) Therefore, if we can introduce the TAA-containing TCL directly into the cytoplasm, the TAAs would be definitively delivered to the MHC class I-antigen presentation pathway, much like cytoplasmic proteins.
Fusion active liposomes (fusogenic liposomes; FLs), which are composed of conventional liposomes (CLs) displaying Sendai virus-accessory proteins, retain membranefusion activity derived from Sendai-virus and efficiently introduce its contents into cytoplasm. 8) We have previously reported that direct antigen loading into cytoplasm by FLs is an efficient approach for enhancing antigen-specific CTL induction in mice. [9] [10] [11] In the present study, in order to evaluate the usefulness of FLs as antigen-delivery carriers for TCL-based cancer immunotherapy, we investigated anti-tumor efficacy of ex vivo vaccination using TCL-containing FLs (TCL/FLs)-pulsed DCs and in vivo direct TCL/FLs-immunization in the murine B16BL6 melanoma model.
MATERIALS AND METHODS
Cells and Mice B16BL6 cells, a C57BL/6-origin melanoma cell line, were grown in Eagle's minimum essential medium supplemented with 10% fetal bovine serum (FBS), and antibiotics. DC2.4 cells, a C57BL/6-derived DC line, 12) were generously provided by Dr. K. L. Rock (Department of Pathology, University of Massachusetts Medical School, Worcester, MA, U.S.A.), and were cultured in RPMI1640 medium supplemented with 10% FBS, 2 mM Lglutamine, 100 mM non-essential amino acid, 50 mM 2-mercaptoethanol, and antibiotics. CD8-OVA 1.3 cells, a T-T hybridoma against OVAϩ H-2Kb, 13) were kindly provided by Dr. C. V. Harding 14) were maintained in RPMI1640 medium supplemented with 10% FBS, 50 mM 2-mercaptoethanol and 10 U/ml murine recombinant IL-2 (Pepro Tech EC Ltd., London, England). Female C57BL/6 mice (H-2b), aged 7-8 weeks, were purchased from SLC Inc. (Hamamatsu, Japan). All of the experimental procedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
Preparation of B16BL6 TCL Cultured B16BL6 cells were recovered and washed three times with phosphatebuffered saline (PBS, pH 7.4). Cells were resuspended in a balanced salt solution (10 mM Tris-HCl, 150 mM NaCl, pH 7.6) and lysed by four cycles of freezing and thawing, followed by centrifugation at 13000 g for 60 min. The soluble fraction was passed through a 0.22-mm membrane filter and the protein concentration was adjusted to 4 mg/ml upon determination with a DC-protein assay kit (Bio-Rad, Tokyo, Japan).
Preparation of CLs and FLs TCL-or ovalbumin (OVA)-containing CLs (TCL/CLs or OVA/CLs) were prepared as follows. Cholesterol, egg phosphatidylcholine, and L-a -dimyristoryl phosphatidic acid were mixed at a molar ratio of 5 : 4 : 1 in chloroform. The lipid mixture was evaporated to obtain a thin-lipid film, and then liposome suspensions were prepared by dispersing the thin-lipid film in 400 ml of TCL or OVA solution. After three cycles of freezing and thawing, the liposomes were sized by two rounds extrusion through 0.8-mm and 0.4-mm polycarbonate membranes and were ultracentrifuged to remove un-encapsulated TCL or OVA. TCL/FLs or OVA/FLs were prepared by fusing the TCL/CLs or OVA/CLs with UV (2000 J/cm 2 )-inactivated Sendai virus as described previously.
9) The amount of antigen proteins encapsulated in liposomes and FLs was measured by a DC-protein assay kit and calculated by following formula: In Vitro Antigen Presentation Assay One hundred microliters of OVA solution, OVA/CLs suspension, or OVA/FLs suspension were added to DC2.4 cells cultured on a 96-well plate at a density of 10 5 cells/well, and the cells were incubated for 5 h at 37°C. After three washes with PBS, DC2.4 cells were co-cultured for 20 h with 10 5 CD8-OVA 1.3 cells. The response of stimulated CD8-OVA 1.3 cells was assessed by the murine IL-2 ELISA kit (Biosource International, Camarillo, CA, U.S.A.), which determines the amount of IL-2 released into 100 ml of culture supernatants. In another experiment, DC2.4 cells were pre-incubated for 1 h at 37°C with 10 mM of lactacystin or MG132 (Peptide Institute, Minoh, Japan), and then the cells were incubated for 15 min at 37°C with OVA/FLs in the presence of inhibitors. After fixation with 0.05% glutaraldehyde and washing three times with PBS, CD8-OVA 1.3 cells were added at 10 5 cells/ 100 ml/well. After 24 h-cultivation, the response of CD8-OVA 1.3 cells was determined by the level of IL-2 secretion in a CTLL-2 proliferation assay as described previously. 15) Ex Vivo Vaccination Experiment Using TCL-Introduced DC2.4 Cells DC2.4 cells were pulsed for 5 h at 37°C with TCL in various formulations (TCL/FLs, TCL/CLs, the mixture of TCL and empty FLs (TCLϩeFLs), or TCL alone) at 500 mg TCL/10 7 cells/ml, and then the cells were treated for 30 min at 37°C with mitomycin C (50 mg/ml) in order to inhibit their proliferation. After three washes with PBS, the cells were intradermally injected into the right flank of C57BL/6 mice at 10 6 cells/50 ml. Likewise, control mice were injected with the unpulsed or eFLs-pulsed DC2.4 cells or PBS. At 1 week after the vaccination, 2ϫ10 Mice containing tumorsϾ20 mm were euthanized. In Vivo Direct Vaccination Experiment C57BL/6 mice were immunized once or three times at a 1-week interval by intradermal injection of each 100 mg-TCL formulation (TCL/FLs, TCL/CLs, TCLϩeFLs, the emulsion of TCL and complete Freund's adjuvant (TCLϩCFA), or TCL alone) into the right flank. Likewise, eFLs or PBS was injected into mice as a control. At 1 week after the final vaccination, 2ϫ10 5 B16BL6 cells were inoculated into the mouse left flank, and then tumor volumes were monitored as described above.
RESULTS

MHC Class I-Restricted OVA-Presentation by OVA/ FLs-Pulsed DC2.4 Cells
We first compared the levels of MHC class I-restricted antigen presentation between DC2.4 cells treated with various OVA formulations (Fig. 1A) . OVA peptide presentation via MHC class I on DC2.4 cells was significantly increased by OVA/FLs-treatment in an OVA dose-dependent manner, whereas OVA/CLs-pulsed DC2.4 cells showed slight enhancement of OVA-presentation as compared with the cells pulsed with the soluble form of OVA. This result suggested that OVA delivered directly into the cytoplasm by FLs imitated endogenous antigens in DC2.4 cells. Thus, in order to investigate the antigen presentation pathway in DC2.4 cells treated with OVA/FLs, we used lactacystin and MG132, which inhibit proteasome activity essential for antigen processing and presentation in the classical MHC class I-pathway (Fig. 1B) . Both inhibitors could completely suppress MHC class I-restricted presentation under conditions that induced high OVA-presentation levels in OVA/FLs-pulsed DC2.4 cells in the absence of inhibitors. In addition, FLs could sufficiently deliver their encapsulating antigen proteins into the MHC class I pathway while in contact with DC2.4 cells for only 15 min. Collectively, antigen introduction by FLs could greatly enhance antigen presentation via MHC class I on APCs, as a result of prompt fusion to the plasma membrane and direct delivery of their encapsulating antigens into cytoplasm.
Vaccine Efficacy of DC2.4 Cells Pulsed with TCL/FLs DC2.4 cells were pulsed with various B16BL6-TCL formulations at 500 mg-TCL/10 7 cells/ml, and then 10 6 cells were intradermally injected into C57BL/6 mice. One week after vaccination, the mice were challenged with B16BL6 cells (Fig. 2) . Mice immunized with eFLs-pulsed or unpulsed DC2.4 cells showed a slight delay in B16BL6 tumor growth as compared with the PBS-injected group. We theorized that this phenomenon was caused by nonspecific immunostimulatory effects that depended on administration of DC2.4 cells. Tumor growth in mice immunized with TCL/CLs-or TCLpulsed DC2.4 cells was comparable to that in control groups injected with eFLs-pulsed or unpulsed DC2.4 cells. In contrast, vaccination with TCL/FLs-pulsed DC2.4 cells markedly delayed tumor growth and suppressed tumor appearance until day 17 post-challenge, when all groups harbored large (Ͼ1000 mm 3 ) tumors. On the other hand, TCLϩeFLs-pulsed DC2.4 cells did not inhibit B16BL6 tumor growth, indicating that the superior vaccine efficacy of TCL/FLs-pulsed DC2.4 cells was the result of efficient TCLdelivery into cytoplasm by FLs. These results clearly revealed that FLs were potential antigen-carriers for the development of DC-based cancer immunotherapy using TCL as antigen source.
Vaccine Efficacy of TCL/FLs by in Vivo Direct Immunization In order to evaluate the vaccine efficacy of TCL/FLs in in vivo direct immunization, we administered various TCL formulations into mice by one or three intradermal injections. In the single immunization mode, mice injected with any TCL formulation, including TCL/FLs, did not exhibit obvious inhibitory effects against the growth of B16BL6 tumors inoculated at 1 week after immunization (Fig. 3A) . On the other hand, triple TCL/FLs-immunization at 1-week intervals dramatically delayed B16BL6 tumor appearance as compared to eFLs-or PBS-administration using the same mode, whereas tumor growth in mice immunized with TCL alone was only slightly suppressed relative to that in the control groups (Fig. 3B) . Although mice immunized three times with TCL/CLs or TCLϩeFLs exhibited moderate inhibition against B16BL6 tumor growth, as was seen in the TCLϩCFA-immunized group, these effects were inferior to those observed in response to TCL/FLs, which prevented the growth of visible tumors in all mice during the 17 d postchallenge. Taken together, these results suggest that FLs are useful antigen-carriers and adjuvants for an in vivo direct TCL-vaccination strategy. itated the development of vaccine strategies for cancer. 16) However, immunotherapeutic application using TAAs as a vaccine component is limited to patients with a particular cancer because TAAs have been identified for only a few human cancers. TCL, which probably includes both known and unknown TAAs, is a very attractive antigen source for the development of versatile cancer immunotherapy. In fact, several studies demonstrated that TCL-pulsed DCs could offer the potential advantage of augmenting a broader T cellimmune response against both defined and undefined TAAs. [17] [18] [19] To improve the CTL response against TCL, we need excellent TCL-delivery carriers and adjuvants that can increase the immunogenicity of weak and rare TAAs. Thus, we evaluated the potential of FLs as a TCL vaccine vehicle in both ex vivo DC-based immunotherapy and in vivo direct vaccination.
We previously reported that FLs, composed of CLs fused with inactivated Sendai virus, could directly introduce their contents into cytoplasm by fusion with the cell membrane. 9, 10) The in vitro antigen presentation assay showed that FLs delivered their encapsulating antigens into the classical MHC class I-restricted pathway for antigen processing and presentation in DC2.4 cells more efficiently than CLs (Fig.  1 ). Other approaches for developing an effective vaccine strategy have also been tested. Shibagaki et al. reported that an HIV-1-derived TAT protein transduction domain (PTD) conjugation technique could directly introduce antigens into cytosol of DCs. 20) Immunization of mice with DCs containing PTD-antigen fusion proteins induced anti-tumor effects through potent antigen-specific CTL activity. 21) However, the application of this technique to DC-based immunotherapy is limited to the treatment of cancer for which TAAs have been identified. In contrast, our antigen delivery system using FLs does not rely on a specific antigen source. Therefore, TCL/FLs-pulsed DC2.4 cells could demonstrate effective vaccine efficacy against B16BL6 tumor challenge (Fig. 2) . This antigen delivery system using FLs against DCs would greatly contribute to the development of DC-based immunotherapy applicable to a wide variety of cancer types.
Furthermore, a triple in vivo direct immunization with TCL/FLs was more effective against B16BL6 tumor growth than the same immunization mode with TCLϩCFA. This result suggested that FLs might efficiently deliver their encapsulating antigen into APCs at the administration site, although it is necessary to examine the biodistribution of antigens and the ratios of APCs containing the antigens after administration of antigen-encapsulating FLs. Additionally, we found that Sendai-virus accessory proteins displayed on FLs possessed mitogenic activity 22) and that FLs could enhance the expression of MHC class I/II molecules and co-stimulatory molecules (CD40 and CD80) and the secretion of IL-6, IL-12 and TNF-a in DCs (unpublished data). Therefore, FLs are not only efficient antigen-delivery carriers but also potential adjuvants in an in vivo direct immunization protocol.
With a view of potential therapeutic use for TCL/FL vaccines, then we tested whether this vaccine would facilitate eradication against established B16 melanoma. However, TCL/FL-immunized mice did not show inhibitory effect against growth of tumors (data not shown). From these results, we hypothesized that the concentration of TAA proteins involved in TCL/FL is too small to induce antimelanoma therapeutic effect. As a potential solution to this problem, tumor cell derived total RNA is useful to induce multiple TAA specific immunity. It has been shown that vaccination with tumor derived RNA transfected DC can be remarkably effective in stimulating CTL and tumor immunity in in vitro and in vivo models. 23, 24) Since multiple TAAs encoded by tumor derived RNA can be amplified from few tumor cells by PCR, FLs might be applicable to transfect it to dendritic cells and in vivo direct immunization strategy.
In conclusion, we demonstrated the usefulness of FLs as TCL-delivery carriers for ex vivo DC-based immunotherapy and in vivo direct immunization in the murine B16BL6 melanoma model. Because FLs can encapsulate various antigen candidates, such as crude tumor lysate or tumor extract, purified whole or partially processed TAA, and TAA-coding DNA or RNA, this simple and flexible system is a promising approach for the development of versatile cancer immunotherapy.
